IL2 and lung carcinoma: Further, our ability to precisely control local dose of therapeutic proteins enables the delivery of proinflammatory cytokines such as interleukin-2 or interleukin-12, which may otherwise cause severe systemic toxicities, for various lung cancer indications70, 71.